Inve US ▾
NVNVST

Envista (NVST) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Health Care· May 6, 2026

Source: earnings call transcript

Executive summary

Envista Q1 FY26 — Strong Start to Year with Broad-Based Growth and Reaffirmed Guidance

Envista delivered a strong start to FY26, extending momentum from prior years with broad-based core revenue growth and significant adjusted EBITDA and EPS expansion. The company reaffirmed its full-year guidance, balancing strong operational execution and new product innovation with ongoing macro and geopolitical uncertainties. Strategic investments in growth and operational efficiency continue to drive performance, alongside an expanded share repurchase authorization.

Highlights

5

  • Core revenue grew 9.5% in Q1 FY26, with all major businesses delivering positive growth.

  • Adjusted EBITDA increased 25% year-over-year, with margins expanding 120 basis points to 14%.

  • Adjusted EPS was $0.36, up 50% compared to the prior year.

  • Gross margin expanded by 100 basis points due to volume, price, productivity, and FX.

  • Board authorized an incremental $300 million addition to the share repurchase program.

Concerns

4

  • Q1 free cash flow was negative $16 million, historically the lowest quarter for cash flow.

  • Implant core growth was low single digits, with strong double-digit declines in China due to VBP process anticipation.

  • Tariff costs increased $11 million in the quarter, expected to be similar going forward.

  • Macro uncertainty and geopolitical shifts, particularly in the Middle East, continue to demand attention.

Guidance & targets

CategoryTargetConfidence
Core Growth
2% to 4%
high materiality
High
Adjusted EBITDA Growth
7% to 13%
high materiality
High
Adjusted EPS
$1.35 to $1.45
high materiality
High
Free Cash Flow Conversion
approximately 100%
medium materiality
High
Non-GAAP Tax Rate
around 28%
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Specialty Products & Technology
Strong growth in orthodontics and developed markets for implants, offset by declines in China due to VBP anticipation. Benefited from positive price capture and factory improvements in orthodontics.
Core sales growth: 8.4%Adjusted operating profit growth: 18%Adjusted operating margin improvement: 40 bpsSpark core growth: double digits (adjusted for net deferral change)Brackets & Wires growth: double digitsImplant core growth: low single digitsImplant core growth ex-China: mid-single digitsImplant core growth in China: down strong double digits
—14%—$10M
Equipment & Consumables
Strong performance in both consumables (Kerr and Metrex) and diagnostics, particularly in developed markets. Driven by strong pricing and volume benefits, offsetting investments in sales, marketing, and R&D. Benefited disproportionately from FX tailwind.
Core sales growth: 11.5%Adjusted operating profit growth: 33%Operating margin up: 300 bpsConsumables growth: double digitsDiagnostics growth: double digits
————
North America
Strong performance.
—double digits——
Europe
Strong performance.
—double digits——
Developing Markets
With some specific exceptions like China due to VBP and the Middle East due to conflict.
—high single digits——

Product announcements

ProductTypeDetails
Nobel S Serieslaunch
Spark in Japanexpansion
DTX Studio Clinic with enhanced AIupdate

Deals & partnerships

Versah Acquisition of a pioneer in osseodensification, a novel implant preparation technique.

Versah offers a patent-protected solution that compacts and autografts bone, leading to improved osteointegration. It simplifies clinical workflows with a universal kit usable with most implant systems and supports more immediate implant placement for patients. Integrates seamlessly into existing clinical education and go-to-market strength.

Risks & headwinds

Macro Volatility / Geopolitical Shifts ongoing

Mid-single-digit million dollar type of risk from fuel increases and related surcharges.

Mitigation:Task forces in place focusing on fuel costs and logistics; supply chain adjustments, internal cost structure optimization, and pricing as a lever for broader inflationary risks.

China VBP Process Q1 FY26 and Q2 FY26

Implant sales in China down strong double digits in Q1 FY26 due to channel inventory reductions.

Mitigation:Company is prepared for the VBP process for both ortho and implants (expected Q2/Q3 FY26); expects long-term benefits from increased market access despite short-term revenue compression.

Tariff Costs FY26

Increased $11 million in Q1 FY26; expected to be similar going forward.

Mitigation:Offset through supply chain, G&A, and pricing actions; new global tariffs effectively replacing prior IEEPA tariffs.

What to watch in Q2 FY26

China Implant Sales & VBP Process

Q2 FY26
Current down strong double digits in Q1
Target Stabilization of channel inventory and start of VBP process

Why it matters

The VBP process will impact short-term revenue and long-term market dynamics in a key growth region.

Implant core growth was up low single digits in the quarter as solid growth in developed markets was offset by declines in China as our channel partners are reducing inventories in preparation for an expected VBP process.

Find out whether NVST delivers this. Inve re-checks your case every morning.

Q&A highlights

What factors are contributing to Envista's positive momentum, and what areas remain challenging?

Paul Keel attributed momentum to improved execution in growth (clinical education, customer support, new product development), operations (EBS, G&A productivity, gross margin expansion), and people (management team, collaboration). Challenges include macro uncertainty and geopolitical shifts, which impact guidance.

“On the growth front, I'd say that the investments we're making in areas like clinical education and customer support and new product development are all beginning to bear fruit.”

asked by Elizabeth Anderson · answered by Paul Keel

2 min read 5 chapters

Detailed narrative

Q1 Performance Overview

Envista reported a strong Q1 FY26, building on momentum from 2024 and 2025. The dental market demonstrated resilience despite macro volatility, with minimal impact from the Middle East situation. The company achieved 9.5% core growth, with all major businesses showing positive growth, including double-digit increases in ortho consumables and diagnostics, and mid-single-digit growth in implants (excluding China).

Strategic Priorities and Execution

The company continued to execute on its three core priorities: growth, operations, and people. Growth was driven by strong performance across the portfolio and new product innovation. Operationally, the Envista Business System improved manufacturing productivity, leading to 100 basis points of gross margin expansion and 120 basis points of adjusted EBITDA margin expansion. People-focused initiatives included improved employee engagement, a new talent development program, and community impact through the Envista Smile project.

New Product Innovation

New products played a central role in accelerating growth. Key launches in Q1 included Nobel S Series in implants, which simplifies workflows and has seen strong early market response. In orthodontics, Spark was launched in Japan, leveraging the company's strong bracket and wire position. DEXIS released DTX Studio Clinic with enhanced AI, offering advanced diagnostics and workflow improvements, processing over 500 million images annually across its large installed base.

Versah Acquisition

Envista completed a small, accretive tuck-in acquisition of Versah, a pioneer in osseodensification, a novel implant preparation technique. This patent-protected solution offers simplified clinical workflows for clinicians and supports more immediate implant placement for patients. The acquisition is expected to be accretive to Envista's growth, margin, EPS, and valuation multiple, integrating into existing clinical education and go-to-market strategies.

Capital Allocation and Financial Strength

The company's improved execution translated into strong financial results, with adjusted EBITDA up 25% and EPS up 50%. This performance supported the board's authorization of an incremental $300 million for the share repurchase program. Envista maintains a strong balance sheet with net debt to adjusted EBITDA of less than 1x, providing flexibility amidst macroeconomic uncertainty.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.